Searched for
RESPIRATORY DRUGS
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Hantavirus scare a wake-up call: Why India must build its disease X defencesA recent hantavirus outbreak on a cruise ship echoes past pandemic scares. Experts warn Disease X, a future unknown pathogen, is a near cer...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Hantavirus scientists were close to vaccine but ran out of moneyScientists in Chile developed antibodies that successfully neutralised the deadly Andes hantavirus in lab and animal studies, raising hopes...
- US market today: Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debutOdyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successf...
- Venus Remedies expands Latin America presence with Argentina nod for antibioticVenus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin Amer...
- Hantavirus scare: Evacuations planned as suspected outbreak traps 150 on ship off Cape VerdeMedics are working to evacuate two individuals with hantavirus symptoms from a luxury cruise ship off West Africa after an outbreak claimed...
- Hantavirus outbreak on cruise ship: Symptoms, treatment, infections in north AmericaHantavirus, which can cause fatal respiratory illness, can be spread when particles from rodent droppings or urine become airborne. It does...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
Load More
